Search Results - Keith Al-Hasani
- Showing 1 - 5 results of 5
-
1
-
2
Pharmacological inhibition of human EZH2 can influence a regenerative β-like cell capacity with in vitro insulin release in pancreatic ductal cells by Safiya Naina Marikar, Keith Al-Hasani, Ishant Khurana, Harikrishnan Kaipananickal, Jun Okabe, Scott Maxwell, Assam El-Osta
Published in Clinical Epigenetics (2023-06-01)Get full text
Article -
3
Inhibition of pancreatic EZH2 restores progenitor insulin in T1D donor by Keith Al-Hasani, Ishant Khurana, Lina Mariana, Thomas Loudovaris, Scott Maxwell, K. N. Harikrishnan, Jun Okabe, Mark E. Cooper, Assam El-Osta
Published in Signal Transduction and Targeted Therapy (2022-07-01)Get full text
Article -
4
EZH2 inhibitors promote β-like cell regeneration in young and adult type 1 diabetes donors by Keith Al-Hasani, Safiya Naina Marikar, Harikrishnan Kaipananickal, Scott Maxwell, Jun Okabe, Ishant Khurana, Thomas Karagiannis, Julia J. Liang, Lina Mariana, Thomas Loudovaris, Thomas Kay, Assam El-Osta
Published in Signal Transduction and Targeted Therapy (2024-01-01)Get full text
Article -
5
Reduced methylation correlates with diabetic nephropathy risk in type 1 diabetes by Ishant Khurana, Harikrishnan Kaipananickal, Scott Maxwell, Sørine Birkelund, Anna Syreeni, Carol Forsblom, Jun Okabe, Mark Ziemann, Antony Kaspi, Haloom Rafehi, Anne Jørgensen, Keith Al-Hasani, Merlin C. Thomas, Guozhi Jiang, Andrea O.Y. Luk, Heung Man Lee, Yu Huang, Yotsapon Thewjitcharoen, Soontaree Nakasatien, Thep Himathongkam, Christopher Fogarty, Rachel Njeim, Assaad Eid, Tine Willum Hansen, Nete Tofte, Evy C. Ottesen, Ronald C.W. Ma, Juliana C.N. Chan, Mark E. Cooper, Peter Rossing, Per-Henrik Groop, Assam El-Osta
Published in The Journal of Clinical Investigation (2023-02-01)Get full text
Article